Clinical trials: Abiraterone Acetate
Prostatic Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
- Trial name
- CYCLONE 3 (NCT05288166)
- Testing
- Abemaciclib, Abiraterone, Prednisone or Prednisolone
- Where
- 266 sites in United States, Argentina and 22 more
- Volunteers
- 925 people
- Sponsor
- Eli Lilly and Company
Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer)
Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC
Acetate abiraterone tablets (II) is a modified new drug launched in China, prepared using nanocrystal technology and supplemented with SNAC as an absorption enhancer, working together to promote the gastrointestinal absorption of…
- Trial name
- mCRPC (NCT06768255)
- Testing
- Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT, Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Ding-Wei Ye
The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
This study is a single-arm, multicenter, phase II exploratory trial. The purpose is to explore the efficacy and safety of Darxicilib in combination with Abiraterone Acetate for the treatment of subjects with metastatic…
- Trial name
- NCT06500247
- Testing
- Dalpicilib, Abiraterone Acetate (II), Androgen Deprivation Therapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Qilu Hospital of Shandong University
Abiraterone Acetate, Gene Polymorphism
Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults
1. To explore the relationship between the changes of plasma concentration of abiraterone acetate after taken orally on fasting or postprandial and gene polymorphism. 2.
- Conditions
- Abiraterone Acetate, Gene Polymorphism, Pharmacokinetic, Metabolic Analysis
- Trial name
- NCT04735913
- Testing
- Abiraterone acetate tablets
- Where
- China
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Advanced Prostate Cancer, Abiraterone ACetate
PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.
PROSABI is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with abiraterone
- Trial name
- PROSABI (NCT02787837)
- Where
- 24 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)
Metastatic castration resistant prostate cancer causes approximately 258400 deaths annually worldwide. In the presence of metastatic disease, systemic treatment remains the main clinical option.
- Trial name
- ARTO (NCT03449719)
- Testing
- SBRT - Ablative radiation Therapy, Abiraterone Acetate
- Volunteers
- 174 people
- Sponsor
- Lorenzo Livi